AGARWALEYE

Dr. Agarwals Health Care Share Price

 

 

Invest in Dr. Agarwals Health Care with 3.6X leverage

Invest with MTF

Performance

  • Low
  • ₹492
  • High
  • ₹506
  • 52 Week Low
  • ₹327
  • 52 Week High
  • ₹568
  • Open Price₹506
  • Previous Close₹506
  • Volume107,363

Investment Returns

  • Over 1 Month -0.8%
  • Over 3 Month + 17.44%
  • Over 6 Month + 35.82%
  • Over 1 Year + 24.3%

Smart Investing Starts Here Start SIP with Dr. Agarwals Health Care for Steady Growth!

Invest Now

Dr. Agarwals Health Care Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 137.8
  • PEG Ratio
  • 4.4
  • Market Cap Cr
  • 15,799
  • P/B Ratio
  • Average True Range
  • 18.36
  • EPS
  • 3.68
  • Dividend Yield
  • 0
  • MACD Signal
  • 1.78
  • RSI
  • 44.1
  • MFI
  • 75.87

Dr. Agarwals Health Care Financials

Dr. Agarwals Health Care Technicals

EMA & SMA

Current Price
₹499.70
-6.3 (-1.25%)
pointer
  • Bearish Moving Average 11
  • Bullish Moving Average 5
  • 20 Day
  • ₹511.14
  • 50 Day
  • ₹502.56
  • 100 Day
  • ₹481.96
  • 200 Day
  • ₹441.15

Resistance and Support

499.23 Pivot Speed
  • R3 520.47
  • R2 513.23
  • R1 506.47
  • S1 492.47
  • S2 485.23
  • S3 478.47

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Dr Agarwal’s Eye Hospitals operate across 13 Indian states and 3 Union Territories, with a flagship center in Chennai. Internationally, the group spans 9 African countries. They offer advanced treatments for cataracts, glaucoma, retina, cornea, and pediatric ophthalmology.

Dr. Agarwal's Health Care Ltd has an operating revenue of Rs. 1,877.05 Cr. on a trailing 12-month basis. An annual revenue growth of 28% is outstanding, Pre-tax margin of 9% is okay, ROE of 4% is fair but needs improvement. The company has a reasonable debt to equity of 8%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 15% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 10% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 61 which is a FAIR score but needs to improve its earnings, a RS Rating of 86 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 45 indicates it belongs to a fair industry group of Medical-Hospitals and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Dr. Agarwals Health Care Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-10-30 Quarterly Results
2025-08-12 Quarterly Results
2025-05-28 Audited Results
2025-02-14 Quarterly Results

Dr. Agarwals Health Care F&O

Dr. Agarwals Health Care Shareholding Pattern

32.42%
5.85%
1.33%
20.11%
0%
1.41%
38.88%

Dr. Agarwals Health Care FAQs

Dr. Agarwals Health Care share price is ₹499 As on 09 December, 2025 | 05:19

The Market Cap of Dr. Agarwals Health Care is ₹15799.1 Cr As on 09 December, 2025 | 05:19

The P/E ratio of Dr. Agarwals Health Care is 137.8 As on 09 December, 2025 | 05:19

The PB ratio of Dr. Agarwals Health Care is 10.5 As on 09 December, 2025 | 05:19

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23